Dimerix Limited (ASX:DXB)

Australia flag Australia · Delayed Price · Currency is AUD
0.5100
-0.0100 (-1.92%)
Sep 26, 2025, 4:12 PM AEST
-1.92%
Market Cap306.09M
Revenue (ttm)5.59M
Net Income (ttm)-13.25M
Shares Out600.18M
EPS (ttm)-0.02
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,202,688
Average Volume1,267,903
Open0.5100
Previous Close0.5200
Day's Range0.5000 - 0.5150
52-Week Range0.3000 - 0.7850
Beta0.31
RSI52.75
Earnings DateNov 23, 2025

About Dimerix

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19; and DMX-700 for orphan respiratory/renal disease, as well as proprietary Receptor-HIT assay technology. The company is headquartered in Fitzroy, Australia. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Nina Webster
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol DXB
Full Company Profile

Financial Performance

In 2025, Dimerix's revenue was 5.59 million, an increase of 1271.12% compared to the previous year's 407,466. Losses were -13.25 million, -22.39% less than in 2024.

Financial Statements

News

Biotech Dimerix lands $940m licensing deal for kidney drug sales

The Melbourne-based company says it has landed one of the biggest licensing deals in Australian biotech history.

5 months ago - The Australian Financial Review